GLP1R and Parkinson disease: A longitudinal population study included 329 patients diagnosed with PD with a median follow-up of 3.33 years; the incidence of PD was 5 per 10,000 person-years in 36,897 patients using DPP4 inhibitors and 4 per 10,000 person-years in 10,684 using GLP-1 agonists.